Being treated in a Comprehensive Cancer Center

Find out more about us

Healthcare professionals

Unicancer care and research

Your page

Find a Center

Retrouvez les Centres de lutte contre le cancer sur l'ensemble du territoire

La recherche

Unicancer research

Find out more


ASCO 2018 highlights for Unicancer and its Centres

The Unicancer network will once again be at the 2018 ASCO (American Society of Clinical Oncology) Congress, the main event for the international oncologoy community, from June 1 to 5 in Chicago. Results from Unicancer-promoted studies will be presented in four oral presentations and posters.

Oral Presentations

Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: the French national AcSé Program

Personalized Medicine Group

Trial: AcSé crizotinib

Authors: Gilles Vassal, Nathalie Cozic, Gilbert Ferretti, Sophie Taïeb, Roch Houot, Laurence Brugières, Thomas Aparicio, Jean-Yves Blay, Ivan Bièche, Sylvie Lantuejoul, Céline Mahier – Ait Oukhatar, Natalie Hoog-Labouret, Denis Moro-Sibilot.


Oral presentation Friday 1 June ; 2:45 PM

abstract  2504 

Poster ASCO 2018 : The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcSé-crizotinib program


Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Unicancer gastro-intestinal Group (UCGI)

Trial: Prodige 24 - Accord 24

Authors :  T. Conroy, P. Hammel, M. Hebbar, M. Ben Abdelghani, A. C. Wei, J.L. Raoul, L. Choné, E. François, P. Artru, J. Biagi, T. Lecomte, E. Assenat, R. Faroux, M. Ychou, J. Volet, A. Sauvanet, C. Jouffroy, P. Rat, F. Castan, J.B. Bachet

Oral presentation Mon. 4 June 3:12 PM - 3:24 PM; Arie Crown Theater

Our press release (French)

ASCO 2018 : un essai ouvre la voie à de nouvelles indications dans plusieurs cancers pour le crizotinib



A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis (PC). PRODIGE 7.

UCGI  Group

Trial: Prodige 7 - Accord 15

Authors: François Quenet1,MD, Dominique Elias2, MD, PhD, Lise Roca1, M.Sc., Diane Goéré2 , MD, PhD, Laurent Ghouti4, MD, Marc Pocard5, MD, PhD, Olivier Facy6, MD, PhD, Catherine Arvieux7, MD, PhD, Gérard Lorimier8, MD, Denis Pezet9, MD, PhD, Frédéric Marchal10, MD, PhD, Valeria Loi11, MD, PhD, Pierre Meeus12, MD, Hélène de Forges1, PhD, Trevor Stanbury14, PhD, Jacques Paineau3, MD, PhD, Olivier Glehen13

Oral presentation Tuesday 5 June ; 10:42 AM - 10:54 AM;  Hall D1



Results of randomized, Placebo (PL)-controlled Phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic Osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer

Sarcoma Group


Authors : Florence Duffaud, Jean-Yves Blay, Olivier Mir, Pascaline Boudou-Rouquette, Sophie Piperno-Neumann, Nicolas Penel, Emmanuelle Bompas, Corinne Delcambre, Elsa Kalbacher, Antoine Italiano, Olivier Collard, Christine Chevreau, Antoine Thyss, Nicolas Isambert, Jessy Delaye, Nicolas De Sousa Carvalho, Camille Schiffler, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud

Oral presentation Monday 4 June  ; 9:12 AM - 9:24 AM heure locale ; Salle : S100a



All presentations on the ASCO planner



PADA-1: a randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients

UCBG group

Trial : : PADA-1

Authors : Francois-Clement Bidard, Renaud Sabatier, Frederique Berger, Barbara Pistilli, Florence Dalenc, Thibault de la Motte Rouge, Jean-Sébastien Frenel, Coraline Dubot, Sylvain Ladoire, Jean-Marc Ferrero, Laetitia Stefani, Alain Lortholary, Anne-Claire Hardy-Bessard, Julien Grenier, Sibille Everhard, Emmanuelle Jeannot, Charlotte Proudhon, Jerome Lemonnier, Suzette Delaloge, Thomas Bachelot

Poster presented Sat, Jun 02, 8:00 AM - 11:30 AM, Poster Board: #183b


Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial

UCGI Group

Trial: PRODIGE 14 - ACCORD 21

Authors : Marc Ychou, Michel Rivoire, Simon Thezenas, Rosine Guimbaud, Francois Ghiringhelli, Anne Mercier Blas, Laurent Mineur, Eric Francois, Faiza Khemissa, Marion Chauvenet, Yves Bécouarn, Philippe Houyau, Thomas Aparicio, Marie Pierre Galais, Franck Audemar, Eric Assenat, Antoine Adenis, Claire Jouffroy-Zeller, Rene Adam, Olivier Bouche

2 posters: Poster Board: #28 et #41


FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

UCGI Group

Trials: PRODIGE 14 - ACCORD 21

Authors : Evelyne Lopez-Crapez, Antoine Adenis, Simon Thezenas, Eric Assenat, Eric Francois, Rosine Guimbaud, Marion Chauvenet, Faiza Khemissa, Franck Audemar, Etienne Suc, Michel Rivoire, François Ghiringhelli, Anne Mercier-Blas, Laurent Mineur, Yves Becouarn, Philippe Houyau, Trevor Stanbury, Claire Jouffroy-Zeller, Olivier Bouche, Marc Ychou

2 posters: Poster Board: #28 et #41


PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (A UNICANCER GI-PRODIGE trial).

UCGI group

Trial: Prodige 52-UCGI 29 IROCAS

Authors : Jaafar Bennouna, Thierry Andre, Laurent Miglianico, Loic Campion, Laurent Mineur, You Heng Lam, Sandrine Hiret, Pascal Artru, Olivier Bouche, Florence Borde, Albert Aleba, Laetitia-Shanna Rajpar, Christine Rebischung, Yann Touchefeu, Petr Kavan, Sharlene Gill, Tim Asmis, Claire Jouffroy-Zeller, Jean-François Emile, Julien Taieb;

Poster board #111b


An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity

Personalized Medicine Group

Trial : Ruby

A. Patsouris, O. Tredan, L.Campion, A. Gonçalves, M. Arnedos, MP. Sablin, P. Jezequel, M. Jimenez, V. Pezzella, I. Bieche, C. Callens, A.Loehr, D. Nenciu, C. Vicier, F. André

Poster #TPS1112   - Poster session : Breast Cancer Metastatic


The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: results from the AcSé-crizotinib program

Personalized Medicine Group

Trial: AcSé crizotinib

Auteurs : Thomas Aparicio, Nathalie Cozic, Christelle De La Fouchardière, Emeline Meriaux, Jérôme Edouard Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte, Carlos Alberto Gomez-Roca, Paul Arthur Haineaux, Alain Gratet, Janick Selves, Yves Menu, Nikias Colignon, Céline Mahier - Ait Oukhatar, Frédéric Legrand, Gilles Vassal

Poster #221089 poster board #243

Contact Presse

Gwendoline Miguel – UNICANCER - 01 76 64 78 00 –